Biotechnology - Licensing, Cardio-vascular

Filter

Current filters:

LicensingCardio-vascular

Popular Filters

Xention and Servier sign up for cardiovascular collaboration

Xention and Servier sign up for cardiovascular collaboration

02-10-2013

Xention and Servier have entered into a multi-year agreement for the development and commercialization…

BiotechnologyCardio-vascularLicensingServierXention

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

Pharming and SIPI collaboration includes Ruconest marketing in China

02-07-2013

Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis

19-06-2013

Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Amgen and Cytokinetics expand omecamtiv mecarbil accord

12-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension

29-05-2013

Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol

05-02-2013

USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

Dezima Pharma in-licenses CETP inhibitor; Imaxio acquires Trolovol

22-01-2013

Netherlands-based biotech firm Dezima Pharma says it has in-licensed a cholesteryl ester transfer protein…

BiotechnologyCardio-vascularDEZ-001Dezima PharmaImaxioLicensingMitsubishi TanabeRare diseasesSpiroleptTrolovol

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments

08-11-2012

US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

Sobi and Biogen Idec flesh out details of hemophilia programs

06-02-2012

Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) and US biotech company Biogen Idec (Nasdaq: BIIB)…

Biogen IdecBiotechnologyCardio-vascularLicensingPharmaceuticalSwedish Orphan Biovitrum

RegeneRx explores strategic options

02-02-2012

US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has…

BiotechnologyCardio-vascularDermatologicalsLicensingNeurologicalOphthalmicsRegeneRx

BioLineRx inks deal with Compugen

14-12-2011

Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top